Sort   by:  
 Page size 
UnknownComparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study.

Background

Recommendations have differed nationally and internationally with respect to the best time to start antiretroviral therapy (ART). We compared effectiveness of three strategies for initiation of ART in high-income countries for HIV-positive individuals who do not have AIDS: immedia...
S-EPMC4643831 | biostudies-literature
UnknownWhole-genome sequencing reveals host factors underlying critical COVID-19.
Critical COVID-19 is caused by immune-mediated inflammatory lung injury. Host genetic variation influences the development of illness requiring critical care1 or hospitalization2-4 after infection with SARS-CoV-2. The GenOMICC (Genetics of Mortality in Critical Care) study enab...
S-EPMC9259496 | biostudies-literature
UnknownGWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19.
Critical illness in COVID-19 is an extreme and clinically homogeneous disease phenotype that we have previously shown1 to be highly efficient for discovery of genetic associations2. Despite the advanced stage of illness at presentation, we have shown that host genetics in patie...
S-EPMC10208981 | biostudies-literature
UnknownEffect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.

Importance

The evidence for benefit of convalescent plasma for critically ill patients with COVID-19 is inconclusive.

Objective

To determine whether convalescent plasma would improve outcomes for critically ill adults with COVID-19.

Design, setting, and participants

The ongoing...
S-EPMC8491132 | biostudies-literature
UnknownEfficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.

Background

Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the se...
S-EPMC7787219 | biostudies-literature
UnknownInterleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.

Background

The efficacy of interleukin-6 receptor antagonists in critically ill patients with coronavirus disease 2019 (Covid-19) is unclear.

Methods

We evaluated tocilizumab and sarilumab in an ongoing international, multifactorial, adaptive platform trial. Adult patients with Covid-...
S-EPMC7953461 | biostudies-literature
UnknownSimvastatin in Critically Ill Patients with Covid-19.

Background

The efficacy of simvastatin in critically ill patients with coronavirus disease 2019 (Covid-19) is unclear.

Methods

In an ongoing international, multifactorial, adaptive platform, randomized, controlled trial, we evaluated simvastatin (80 mg daily) as compared with no stati...
S-EPMC10755839 | biostudies-literature
UnknownMapping the human genetic architecture of COVID-19.
The genetic make-up of an individual contributes to the susceptibility and response to viral infection. Although environmental, clinical and social factors have a role in the chance of exposure to SARS-CoV-2 and the severity of COVID-191,2, host genetics may also be important. Identifying...
S-EPMC8674144 | biostudies-literature
UnknownLopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial.

Purpose

To study the efficacy of lopinavir-ritonavir and hydroxychloroquine in critically ill patients with coronavirus disease 2019 (COVID-19).

Methods

Critically ill adults with COVID-19 were randomized to receive lopinavir-ritonavir, hydroxychloroquine, combination therapy of lopin...
S-EPMC8274471 | biostudies-literature
UnknownTherapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.

Background

Thrombosis and inflammation may contribute to the risk of death and complications among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation may improve outcomes in noncritically ill patients who are hospitalized with Covid-19.
S-EPMC8362594 | biostudies-literature
Sort   by:  
 Page size